Skip to content
Screener

ImmunityBio, Inc. IBRX Q2 2025 earnings

Reported August 5, 2025 · Before market open

Revenue$26.4MMiss by $5.5M
EPS-$0.10In line
Revenue estimate$31.9M
EPS estimate-$0.10

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$59.2M
EPS estimate-$0.08

Financials

Q2 2025

Income statement

See full
Revenue$26.4M+2,424%
Gross profit$26.3M+2,411%
Operating income-$71.3M+28.2%
Net income-$92.6M+31.2%
EPS (diluted)-$0.10+50.0%

Balance sheet

See full
Cash & equivalents$137.7M+5.8%
Total debt$308.0M+0.6%
Total equity-$570.7M+18.3%
Total assets$402.1M-9.5%

Cash flow

See full
Operating cash flow-$79.7M+20.5%
CapEx$1.1M+49.3%
Free cash flow-$80.8M+20.0%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$2.46B-43.3%
Enterprise value$2.63B-41.7%
P/S43.5×-3,276×

Profitability

See full
Gross margin99.7%-0.3pp
Operating margin-504.2%-250pp
Net margin-648.6%-322pp
FCF margin-630.1%-312pp

Returns & leverage

See full
Current ratio4.1×+0.2×

Segments

By segment

See full
Reportable Segment$26.4M+2,424%

FAQ

When did ImmunityBio, Inc. report Q2 2025 earnings?
ImmunityBio, Inc. (IBRX) reported Q2 2025 earnings on August 5, 2025 before market open.
What were ImmunityBio, Inc.'s Q2 2025 revenue and EPS?
ImmunityBio, Inc. reported revenue of $26.4M and eps of $-0.10 for Q2 2025.
Did ImmunityBio, Inc. beat estimates in Q2 2025?
Revenue missed the consensus estimate of $31.9M by $5.5M. EPS beat the consensus estimate of $-0.10 by $0.00.
How did ImmunityBio, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2423.9% from $1.0M a year earlier and eps grew 50.0% from $-0.20.
Where can I find ImmunityBio, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001326110-25-000112) and the 10-Q periodic report (0001326110-25-000114) directly on SEC EDGAR. The filing index links above go to sec.gov.